4月1日 - ** 药物开发商Compass Therapeutics CMPX.O股价下跌14.5%，至1.62美元
** CMPX表示，其实验性胆道癌症药物tovecimig与化疗联合使用时，患者的总体反应率$(ORR.AU)$ 为17.1%，而单独接受化疗的患者的总体反应率仅为5.3%。
** ORR是指在预定时间内肿瘤缩小或消失的患者比例。
** 经纪公司 Leerink Partners 称，这一反应率低于预期，也低于之前的试验结果。
** 券商称，阿斯利康AZN.L的Enhertu和IncyteINCY.O的Pemazyre等其他疗法在类似患者群体中显示出更高的反应率
** 包括会议期间的走势在内，CMPX 的股价今年以来上涨了 31
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.